Oric Pharmaceuticals Inc. (ORIC)
Summary
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
Oric Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 372,904 | $3.01M | $4.54M | $1.53M | 50.92% |
 Curtis Ellergodt Rothschild Investment LLC | 77 | $656.61 | $928.23 | $271.62 | 41.37% |
| BG Bart Gancher Intech Investment Management LLC | 20,143 | $141,007.64 | $271,930.5 | $130,922.86 | 92.85% |
 Joseph Castro Nuveen LLC | 172,167 | $1.22M | $2.07M | $846,271.36 | 69.19% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 46 | $467.13 | $638.02 | $170.89 | 36.58% |
Oric Pharmaceuticals Inc. (ORIC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oric Pharmaceuticals Inc. ever had a stock split?
Oric Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jacob Chacko CEO | NASDAQ (NGS) Exchange | 68622P109 CUSIP |
| US Country | 111 Employees | - Last Dividend | - Last Split | 24 Apr 2020 IPO Date |
Overview
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies aimed at treating cancers. With its operations primarily based in the United States, ORIC Pharmaceuticals is on a mission to confront and conquer cancer resistance mechanisms by advancing a diverse pipeline of promising therapeutic candidates. The company's strategy involves a blend of in-house research and development, strategic collaborations, and licensing agreements with other biotech entities to bolster its portfolio and expedite the development of its drug candidates. Founded in 2014, ORIC Pharmaceuticals has established its headquarters in South San Francisco, California, positioning itself in one of the nation's leading biotechnology hubs.
Products and Services
- ORIC-114
An advanced, brain penetrant, orally bioavailable irreversible inhibitor aimed at targeting specific mutations within the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). ORIC-114 is in a Phase 1b clinical trial stage, focusing on addressing exon 20 insertion mutations noted for their role in various cancers. The development of ORIC-114 underscores ORIC Pharmaceuticals’ commitment to tackling specific, challenging targets in oncology with high precision.
- ORIC-944
Enrolled in Phase 1b clinical trials, ORIC-944 is an allosteric inhibitor specifically designed to disrupt the functioning of the polycomb repressive complex 2 (PRC2), a critical player in the epigenetic regulation of genes. By targeting PRC2, ORIC-944 is being investigated for its potential in treating prostate cancer, demonstrating ORIC Pharmaceuticals' dedication to exploring novel pathways in cancer treatment.
- ORIC-533
This orally bioavailable small molecule inhibitor of CD73 is under a Phase 1b study to evaluate its efficacy in overcoming resistance to established chemotherapy- and immunotherapy-based treatment regimens. By inhibiting CD73, ORIC-533 aims to enhance anti-tumor immune responses, positioning it as a potential new pillar in cancer therapy, particularly for patients who have developed resistance to existing treatments.
- Discovery Stage Precision Medicines
Among its diverse portfolio, ORIC Pharmaceuticals is also progressing multiple discovery stage precision medicines. Notably, ORIC-613, a highly selective inhibitor of PLK4 (polo-like kinase 4), is being researched in preclinical studies for its therapeutic potential against breast cancers. ORIC-613 exemplifies the company’s effort to expand its research into mechanisms and targets that could offer new avenues for cancer treatment.
In addition to its robust pipeline, ORIC Pharmaceuticals has entered into key partnerships to advance its mission, including a license and collaboration agreement with Voronoi Inc., a license agreement with Mirati Therapeutics, Inc., and a clinical development collaboration with Pfizer Inc. These strategic alliances are crucial for enhancing ORIC Pharmaceuticals' capabilities in bringing innovative cancer treatments from the laboratory to the clinic and ultimately to patients in need.
